BusinessASLAN Pharmaceuticals Announces Presentation of New Pre-Clinical Data on Varlitinib in Hepatocellular Carcinoma at AACRBy Nasdaq OMXApr 17, 2018, 1:29 PM UTC
BusinessAslan Pharmaceuticals Files for Proposed Initial Public Offering in the U.S.By Nasdaq OMXMar 27, 2018, 1:00 AM UTC
BusinessASLAN Pharmaceuticals Appoints Stephen Doyle as Head of ChinaBy Nasdaq OMXJan 18, 2018, 6:00 AM UTC
BusinessASLAN Pharmaceuticals Announces Shortened Timeline to Commercialisation for Varlitinib in ChinaBy Nasdaq OMXJan 8, 2018, 6:00 AM UTC
BusinessASLAN Pharmaceuticals to Present at J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 4, 2018, 7:00 AM UTC
BusinessASLAN Pharmaceuticals Acquires Full Global Commercial Rights for Varlitinib From Array BioPharmaBy Nasdaq OMXJan 3, 2018, 8:00 AM UTC
